| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human LRIG1 recombinant protein (Position: K79-E906) was used as the immunogen for the LRIG1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
LRIG1 Antibody / Leucine-rich repeats and immunoglobulin-like domains protein 1 is a anti-LRIG1 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human.
Key elements and design rationale
- Target: LRIG1
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
LRIG1 localizes primarily to the plasma membrane but can also be detected in intracellular vesicles and the nucleus. It negatively regulates EGFR, ERBB2, and ERBB3 signaling by recruiting E3 ubiquitin ligases such as CBL to target receptors for degradation. In addition to receptor regulation, LRIG1 functions as a stem cell marker in epithelial tissues, maintaining quiescence and tissue renewal capacity. In the intestine and skin, LRIG1 marks long-lived stem cells essential for tissue homeostasis.
The LRIG1 antibody is widely used in cancer biology, stem cell, and developmental research to study growth factor receptor regulation, cell differentiation, and tumor suppression. Western blot analysis identifies a 120-150 kilodalton band corresponding to LRIG1, while immunohistochemistry reveals membrane and cytoplasmic staining in epithelial and neural tissues. This antibody supports investigations into receptor turnover, oncogenic signaling, and epithelial regeneration.
Loss or downregulation of LRIG1 is associated with tumor progression in gliomas, breast, and colorectal cancers due to hyperactivation of growth factor signaling. Conversely, overexpression suppresses tumor growth by dampening EGFR pathway activity. The LRIG1 antibody provides a reliable tool for studying receptor regulation, epithelial biology, and cancer suppression.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
